<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603902</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-011</org_study_id>
    <nct_id>NCT00603902</nct_id>
  </id_info>
  <brief_title>BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management</brief_title>
  <official_title>A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the weight loss effect of lorcaserin during and at the
      end of 1 year of treatment in overweight and obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, parallel-group assessment of the effects of
      lorcaserin hydrochloride during 52 weeks of administration to overweight or obese male and
      female volunteers aged 18 to 65 years inclusive.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary Endpoint- Proportion (%) of Patients Achieving &gt; or = 5% Weight Loss From Baseline to Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The proportion of patients with a reduction from baseline body weight of 5% or more after 52 weeks.
Other co-primary endpoints are change from baseline in body weight (kg) at year 1 and the proportion of patients achieving â‰¥ 10% reduction in body weight at year 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>The % change in body weight (kg) from baseline to week 52.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4008</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lorcaserin 10 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorcaserin 10 mg tablet each morning and placebo tablet each evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorcaserin 10 mg tablet each morning and evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet each morning and evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin 10 mg QD</intervention_name>
    <description>Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.</description>
    <arm_group_label>Lorcaserin 10 mg QD</arm_group_label>
    <other_name>APD356</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin 10 mg BID</intervention_name>
    <description>Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.</description>
    <arm_group_label>Lorcaserin 10 mg BID</arm_group_label>
    <other_name>APD356</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching placebo tablet each morning and evening for a duration of 52 weeks.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight and/or obese men and women with a body mass index (BMI) 30 to 45 kg/m2 with
             or without a comorbid condition (e.g., hypertension, dyslipidemia, CV disease, glucose
             intolerance, sleep apnea), or 27 to 29.9 kg/m2 with at least one comorbid condition.

          -  Ability to complete a 1 year study

        Exclusion Criteria:

          -  Pregnancy

          -  Diabetes mellitus (type I, II or other)

          -  History of symptomatic heart valve disease

          -  Serious or unstable current or past medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Shanahan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arena Pharmaceuticals, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.arenapharm.com</url>
    <description>Arena Pharmaceuticals, Inc. Home Page</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <results_first_submitted>January 4, 2013</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2013</results_first_posted>
  <disposition_first_submitted>July 26, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 6, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 14, 2012</disposition_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Weight loss</keyword>
  <keyword>lorcaserin</keyword>
  <keyword>APD356</keyword>
  <keyword>BLOSSOM</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>glucose tolerance</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>Arena</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lorcaserin 10 mg QD</title>
          <description>lorcaserin 10 mg QD tablets</description>
        </group>
        <group group_id="P2">
          <title>Lorcaserin 10 mg BID</title>
          <description>lorcaserin 10 mg BID tablets</description>
        </group>
        <group group_id="P3">
          <title>Matching Placebo</title>
          <description>matching placebo tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="802"/>
                <participants group_id="P2" count="1603"/>
                <participants group_id="P3" count="1603"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="473"/>
                <participants group_id="P2" count="917"/>
                <participants group_id="P3" count="834"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="686"/>
                <participants group_id="P3" count="769"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lorcaserin 10 mg QD</title>
          <description>lorcaserin 10 mg QD tablets</description>
        </group>
        <group group_id="B2">
          <title>Lorcaserin 10 mg BID</title>
          <description>lorcaserin 10 mg BID tablets</description>
        </group>
        <group group_id="B3">
          <title>Matching Placebo</title>
          <description>matching placebo tablets</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="801"/>
            <count group_id="B2" value="1602"/>
            <count group_id="B3" value="1601"/>
            <count group_id="B4" value="4004"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="11.66"/>
                    <measurement group_id="B2" value="43.8" spread="11.81"/>
                    <measurement group_id="B3" value="43.7" spread="11.76"/>
                    <measurement group_id="B4" value="43.8" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="656"/>
                    <measurement group_id="B2" value="1289"/>
                    <measurement group_id="B3" value="1249"/>
                    <measurement group_id="B4" value="3194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="313"/>
                    <measurement group_id="B3" value="352"/>
                    <measurement group_id="B4" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-primary Endpoint- Proportion (%) of Patients Achieving &gt; or = 5% Weight Loss From Baseline to Week 52</title>
        <description>The proportion of patients with a reduction from baseline body weight of 5% or more after 52 weeks.
Other co-primary endpoints are change from baseline in body weight (kg) at year 1 and the proportion of patients achieving â‰¥ 10% reduction in body weight at year 1.</description>
        <time_frame>52 weeks</time_frame>
        <population>MITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin 10 mg QD</title>
            <description>lorcaserin 10 mg QD tablets</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin 10 mg BID</title>
            <description>lorcaserin 10 mg BID tablets</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>matching placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary Endpoint- Proportion (%) of Patients Achieving &gt; or = 5% Weight Loss From Baseline to Week 52</title>
          <description>The proportion of patients with a reduction from baseline body weight of 5% or more after 52 weeks.
Other co-primary endpoints are change from baseline in body weight (kg) at year 1 and the proportion of patients achieving â‰¥ 10% reduction in body weight at year 1.</description>
          <population>MITT with LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="771"/>
                <count group_id="O2" value="1561"/>
                <count group_id="O3" value="1541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjustments for baseline body weight.</method_desc>
            <param_type>Odds Ratio, log</param_type>
            <param_value>2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.31</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 52</title>
        <description>The % change in body weight (kg) from baseline to week 52.</description>
        <time_frame>52 weeks</time_frame>
        <population>MITT with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin 10 mg QD</title>
            <description>lorcaserin 10 mg QD tablets</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin 10 mg BID</title>
            <description>lorcaserin 10 mg BID tablets</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>matching placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 52</title>
          <description>The % change in body weight (kg) from baseline to week 52.</description>
          <population>MITT with LOCF</population>
          <units>% change from baseline: body wt (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="771"/>
                <count group_id="O2" value="1561"/>
                <count group_id="O3" value="1541"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.75" spread="0.23"/>
                    <measurement group_id="O2" value="-5.84" spread="0.16"/>
                    <measurement group_id="O3" value="-2.84" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>-2.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lorcaserin 10 mg QD</title>
          <description>lorcaserin 10 mg QD tablets</description>
        </group>
        <group group_id="E2">
          <title>Lorcaserin 10 mg BID</title>
          <description>lorcaserin 10 mg BID tablets</description>
        </group>
        <group group_id="E3">
          <title>Matching Placebo</title>
          <description>matching placebo tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="801"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1602"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Oral mucosal hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Anthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage I, with cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Tethered cord syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Uterine mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Ovarian necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1602"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="801"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="653" subjects_at_risk="801"/>
                <counts group_id="E2" subjects_affected="1323" subjects_at_risk="1602"/>
                <counts group_id="E3" subjects_affected="1205" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="68" subjects_affected="61" subjects_at_risk="801"/>
                <counts group_id="E2" events="160" subjects_affected="145" subjects_at_risk="1602"/>
                <counts group_id="E3" events="96" subjects_affected="85" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="801"/>
                <counts group_id="E2" events="119" subjects_affected="98" subjects_at_risk="1602"/>
                <counts group_id="E3" events="106" subjects_affected="94" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="801"/>
                <counts group_id="E2" events="91" subjects_affected="80" subjects_at_risk="1602"/>
                <counts group_id="E3" events="62" subjects_affected="61" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="801"/>
                <counts group_id="E2" events="90" subjects_affected="87" subjects_at_risk="1602"/>
                <counts group_id="E3" events="41" subjects_affected="37" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="801"/>
                <counts group_id="E2" events="147" subjects_affected="134" subjects_at_risk="1602"/>
                <counts group_id="E3" events="71" subjects_affected="66" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="142" subjects_affected="117" subjects_at_risk="801"/>
                <counts group_id="E2" events="247" subjects_affected="204" subjects_at_risk="1602"/>
                <counts group_id="E3" events="238" subjects_affected="202" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="123" subjects_affected="95" subjects_at_risk="801"/>
                <counts group_id="E2" events="240" subjects_affected="201" subjects_at_risk="1602"/>
                <counts group_id="E3" events="240" subjects_affected="192" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="77" subjects_affected="67" subjects_at_risk="801"/>
                <counts group_id="E2" events="141" subjects_affected="122" subjects_at_risk="1602"/>
                <counts group_id="E3" events="132" subjects_affected="118" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="80" subjects_affected="61" subjects_at_risk="801"/>
                <counts group_id="E2" events="131" subjects_affected="107" subjects_at_risk="1602"/>
                <counts group_id="E3" events="84" subjects_affected="77" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="60" subjects_affected="55" subjects_at_risk="801"/>
                <counts group_id="E2" events="107" subjects_affected="101" subjects_at_risk="1602"/>
                <counts group_id="E3" events="107" subjects_affected="91" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="158" subjects_affected="125" subjects_at_risk="801"/>
                <counts group_id="E2" events="293" subjects_affected="250" subjects_at_risk="1602"/>
                <counts group_id="E3" events="172" subjects_affected="147" subjects_at_risk="1601"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="58" subjects_affected="50" subjects_at_risk="801"/>
                <counts group_id="E2" events="169" subjects_affected="140" subjects_at_risk="1602"/>
                <counts group_id="E3" events="72" subjects_affected="62" subjects_at_risk="1601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of study results are only allowed with prior written consent from Arena Pharmaceuticals, Inc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Operations</name_or_title>
      <organization>Arena Pharmaceuticals, Inc.</organization>
      <phone>858-453-7200 ext 1602</phone>
      <email>sstubbe@arenapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

